Imatinib mesylate: Recent drug used in oncology

Background: The European Union and Canada have approved generic imatinib for the treatment of chronic myeloid leukaemia (EU). Anecdotal evidence suggests that performs less well than brand-name imatinib. MEDLINE EMBASE were searched as methods. Medicines Agency (EMA) Health Canada-approved product monographs examined. We contacted Novartis, Teva, Apotex's medical information. Results: A number issues been brought up. First, outside EU has linked to inconsistent results in two case series lower efficacy minor reports. However, it is unclear whether these products' clinical bioequivalence established. Second, there concerns raised about imatinib's use different populations. compared adults with leukaemia, absorption not significantly children or patients gastrointestinal tumours. Even though reports reduced following gastric bypass gastrectomy, majority absorbed ileum, duodenum, colon, jejunum. It also demonstrated changes stomach acidity no impact on absorption. At room temperature, beta-crystal form more stable alpha-crystal EMA discovered both crystal forms extremely soluble polymorphism would materially affect